title: Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.
abstract: CXCR4 regulates hematopoietic and tumor cell homing to bone, but its role during osteoclast (OC) development is unknown. We investigated the role of CXCR4 in osteoclastogenesis and in a model of bone metastasis. Compared with controls, mice reconstituted with CXCR4 null hematopoietic cells exhibited elevated markers of bone resorption, increased OC perimeter along bone, and increased bone loss. CXCR4-/- OCs demonstrated accelerated differentiation and enhanced bone resorption in vitro. Furthermore, tumor growth specifically in bone was significantly increased in mice reconstituted with CXCR4-/- hematopoietic cells. Finally, enhancement of bone tumor growth in the absence of CXCR4 was abrogated with the OC inhibitor, zoledronic acid. These data demonstrate that disruption of CXCR4 enhances osteoclastogenesis and suggest that inhibition of CXCR4 may enhance established skeletal tumor burden by increasing OC activity.
authors: Department of Medicine, Division of Oncology, Washington University School of Medicine, 660 South Euclid Avenue, St. Louis, MO 63110, USA.
authors: Angela C
authors: AC
authors: Hirbe
authors: Jessica
authors: J
authors: Rubin
authors: Ozge
authors: O
authors: Uluçkan
authors: Elizabeth A
authors: EA
authors: Morgan
authors: Mark C
authors: MC
authors: Eagleton
authors: Julie L
authors: JL
authors: Prior
authors: David
authors: D
authors: Piwnica-Worms
authors: Katherine N
authors: KN
authors: Weilbaecher
mesh_terms: D000818:Animals; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000235:genetics / Q000473:pathology*; D001862:Bone Resorption; D002455:Cell Division; D004164:Diphosphonates / Q000627:therapeutic use; D007093:Imidazoles / Q000627:therapeutic use; D007700:Kinetics; D008264:Macrophages / Q000473:pathology / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D009362:Neoplasm Metastasis; D010010:Osteoclasts / Q000473:pathology; D019718:Receptors, CXCR4 / Q000172:deficiency / Q000235:genetics*; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; C514936:CXCR4 protein, mouse; D004164:Diphosphonates; D007093:Imidazoles; D019718:Receptors, CXCR4; D000077211:Zoledronic Acid
references: Blood. 2005 Nov 1;106(9):3020-7
references: 16037394
references: J Exp Med. 1997 Jan 6;185(1):111-20
references: 8996247
references: J Bone Miner Res. 2005 Dec;20(12):2116-23
references: 16294265
references: Immunol Rev. 2005 Dec;208:88-105
references: 16313343
references: Nature. 2006 Mar 30;440(7084):692-6
references: 16572175
references: Ann N Y Acad Sci. 2006 Apr;1068:165-72
references: 16831915
references: J Exp Med. 2006 Sep 4;203(9):2201-13
references: 16940167
references: Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6309s-6314s
references: 17062720
references: Biochem Biophys Res Commun. 2006 Dec 8;351(1):99-105
references: 17052691
references: Nat Med. 2007 Jan;13(1):62-9
references: 17159986
references: Nature. 2007 Feb 22;445(7130):E19; discussion E19-20
references: 17314931
references: Blood. 2007 Apr 15;109(8):3424-31
references: 17192391
references: Blood. 2007 Apr 1;109(7):2708-17
references: 17119115
references: Cell Mol Immunol. 2004 Apr;1(2):95-104
references: 16212895
references: J Clin Invest. 1999 Nov;104(9):1199-211
references: 10545519
references: Cancer. 2000 Jun 15;88(12 Suppl):2892-8
references: 10898330
references: J Biol Chem. 2001 Oct 19;276(42):39295-302
references: 11514537
references: Cancer Res. 2002 Mar 15;62(6):1832-7
references: 11912162
references: J Biol Chem. 2002 Apr 19;277(16):14221-6
references: 11827970
references: J Clin Oncol. 2002 Aug 1;20(15):3219-24
references: 12149294
references: Nat Rev Cancer. 2002 Aug;2(8):584-93
references: 12154351
references: Leukemia. 2002 Oct;16(10):1992-2003
references: 12357350
references: J Immunol. 2002 Nov 15;169(10):5546-54
references: 12421931
references: Traffic. 2003 Feb;4(2):113-25
references: 12559037
references: Anticancer Res. 2003 Mar-Apr;23(2A):1027-9
references: 12820342
references: Cancer Cell. 2003 Jun;3(6):537-49
references: 12842083
references: Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13513-8
references: 14595012
references: Histochem Cell Biol. 2003 Nov;120(5):391-400
references: 14600836
references: Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14205-10
references: 14612570
references: Nature. 1996 Aug 15;382(6592):635-8
references: 8757135
references: Clin Exp Metastasis. 1992 Nov;10(6):411-8
references: 1451351
references: Nature. 1998 Jun 11;393(6685):591-4
references: 9634237
references: Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9448-53
references: 9689100
references: Cancer Res. 2004 Dec 1;64(23):8604-12
references: 15574767
references: J Bone Miner Res. 2005 Feb;20(2):318-29
references: 15647826
references: J Biol Chem. 2005 Mar 25;280(12):11395-403
references: 15647289
references: Bone. 2005 May;36(5):840-53
references: 15794931
references: IUBMB Life. 2005 Jun;57(6):389-95
references: 16012047
references: J Mammary Gland Biol Neoplasia. 2005 Apr;10(2):169-80
references: 16025223
references: Blood. 2005 Sep 1;106(5):1867-74
references: 15890685
references: J Biol Chem. 2005 Oct 21;280(42):35760-6
references: 16107333
references: Stem Cells. 2004;22(1):109-18
references: 14688397
references: N Engl J Med. 2004 Apr 15;350(16):1655-64
references: 15084698
references: Trends Immunol. 2004 Jun;25(6):306-14
references: 15145320
references: J Mol Histol. 2004 Mar;35(3):233-45
references: 15339043
references: J Bone Miner Res. 1987 Dec;2(6):595-610
references: 3455637
references: Arthritis Res Ther. 2005;7(6):R1208-20
references: 16277673